Can-Fite BioPharma Ltd. (CANF.TA)
ILA 1.6
(6.67%)
ILA 1.6
(6.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.63 Million USD | 27.52% |
| 2022 | -10.53 Million USD | 16.37% |
| 2021 | -12.59 Million USD | 14.93% |
| 2020 | -14.8 Million USD | -13.44% |
| 2019 | -13.05 Million USD | -98.63% |
| 2018 | -6.57 Million USD | -32.25% |
| 2017 | -4.96 Million USD | 27.96% |
| 2016 | -6.89 Million USD | -43.79% |
| 2015 | -4.79 Million USD | 21.38% |
| 2014 | -6.1 Million USD | 26.85% |
| 2013 | -8.34 Million ILS | -49.68% |
| 2012 | -5.57 Million USD | 16.82% |
| 2011 | -6.69 Million USD | -82.18% |
| 2010 | -3.67 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | -1.65 Million USD | 6.24% |
| 2023 FY | -7.63 Million USD | 27.52% |
| 2023 Q2 | -1.67 Million USD | 30.07% |
| 2023 Q1 | -2.38 Million USD | 19.19% |
| 2023 Q3 | -1.76 Million USD | -5.51% |
| 2022 Q1 | -2.56 Million USD | 37.79% |
| 2022 FY | -10.53 Million USD | 16.37% |
| 2022 Q2 | -2.43 Million USD | 5.04% |
| 2022 Q3 | -2.44 Million USD | -0.33% |
| 2022 Q4 | -2.95 Million USD | -21.06% |
| 2021 FY | -12.59 Million USD | 14.93% |
| 2021 Q2 | -3.21 Million USD | -71.41% |
| 2021 Q1 | -1.87 Million USD | 48.31% |
| 2021 Q3 | -3.4 Million USD | -5.62% |
| 2021 Q4 | -4.11 Million USD | -21.12% |
| 2020 Q2 | -3.89 Million USD | 10.34% |
| 2020 FY | -14.8 Million USD | -13.44% |
| 2020 Q1 | -4.34 Million USD | -148.68% |
| 2020 Q4 | -3.63 Million USD | -41.09% |
| 2020 Q3 | -2.57 Million USD | 33.86% |
| 2019 FY | -13.05 Million USD | -98.63% |
| 2019 Q2 | -3.06 Million USD | -67.09% |
| 2019 Q3 | -2.94 Million USD | 3.69% |
| 2019 Q4 | -1.74 Million USD | 40.77% |
| 2019 Q1 | -1.83 Million USD | 46.57% |
| 2018 FY | -6.57 Million USD | -32.25% |
| 2018 Q4 | -3.42 Million USD | -1837.29% |
| 2018 Q3 | -177 Thousand USD | 85.77% |
| 2018 Q2 | -1.24 Million USD | 27.72% |
| 2018 Q1 | -1.72 Million USD | -60.2% |
| 2017 Q1 | -1.28 Million USD | 27.01% |
| 2017 FY | -4.96 Million USD | 27.96% |
| 2017 Q4 | -1.07 Million USD | -114.03% |
| 2017 Q3 | -501.9 Thousand USD | 76.2% |
| 2017 Q2 | -2.1 Million USD | -64.29% |
| 2016 Q3 | -2.23 Million USD | -62.82% |
| 2016 Q1 | -1.52 Million USD | -664.3% |
| 2016 Q2 | -1.37 Million USD | 9.96% |
| 2016 Q4 | -1.75 Million USD | 21.42% |
| 2016 FY | -6.89 Million USD | -43.79% |
| 2015 Q4 | 270.51 Thousand USD | 109.08% |
| 2015 Q1 | -343.46 Thousand USD | 79.31% |
| 2015 Q2 | -1.74 Million USD | -408.39% |
| 2015 Q3 | -2.97 Million USD | -70.55% |
| 2015 FY | -4.79 Million USD | 21.38% |
| 2014 Q2 | -1.77 Million USD | -3.38% |
| 2014 Q3 | -941.6 Thousand USD | 47.07% |
| 2014 FY | -6.1 Million USD | 26.85% |
| 2014 Q4 | -1.66 Million USD | -76.31% |
| 2014 Q1 | -1.72 Million USD | 47.75% |
| 2013 FY | -8.34 Million ILS | -49.68% |
| 2013 Q1 | -2.03 Million USD | 78.13% |
| 2013 Q4 | -3.29 Million USD | -140.44% |
| 2013 Q2 | -1.55 Million USD | 23.54% |
| 2013 Q3 | -1.36 Million USD | 12.06% |
| 2012 FY | -5.57 Million USD | 16.82% |
| 2012 Q4 | -9.31 Million USD | -682.61% |
| 2012 Q2 | -1.22 Million USD | -21.66% |
| 2012 Q1 | -1 Million USD | 69.92% |
| 2012 Q3 | 1.59 Million USD | 231.01% |
| 2011 Q1 | -1.42 Million USD | -22.23% |
| 2011 FY | -6.69 Million USD | -82.18% |
| 2011 Q2 | -1.23 Million USD | 13.18% |
| 2011 Q3 | -898.05 Thousand USD | 27.5% |
| 2011 Q4 | -3.33 Million USD | -271.36% |
| 2010 Q3 | -969.94 Thousand USD | 0.0% |
| 2010 FY | -3.67 Million USD | 0.0% |
| 2010 Q4 | -1.16 Million USD | -20.34% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Matricelf Ltd | -12.48 Million ILA | 38.86% |